(Q47652162)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677117%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677117%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

0 references

0 references

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677117%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Ingrid Ordas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677117%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Aranzazu Jauregui-Amezaga

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677117%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Fanny Turon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677117%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Marta Gallego

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677117%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Faust Feu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677117%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Elena Ricart

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677117%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

5 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677117%20AND%20SRC:MED&resulttype=core&format=json

Journal of Crohn's and Colitis

4 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677117%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677117%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677117%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

208-212

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677117%20AND%20SRC:MED&resulttype=core&format=json

Mucosal healing and anti TNFs in IBD.

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Screening for tuberculosis infection prior to initiation of anti-TNF therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Interferon gamma release assays: principles and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Consensus document on the diagnosis, treatment and prevention of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012

Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.05.012